Immunomedics Inc

Immunomedics — Proxy Contest (January 2017)

38 slides from Immunomedics's proxy contest presentation, Jan 26, 2017

  1. Slide 1: The Case for Change at Immunomedics, Inc. (IMMU)

    The Case for Change at Immunomedics, Inc. (IMMU)

  2. Slide 2: Disclosures/Disclaimer

    Disclosures/Disclaimer venBio Select Advisor LLC, ("venBio") Behzad Aghazadeh, Scott Canute, Peter Barton Hutt and Khalid Islam (collectively, the “Participants”) have filed with the Securities and Exchange Commission (the “SEC”) a definitive proxy statement and accompanying form of proxy to be used

  3. Slide 3: Executive Summary

    Executive Summary 1. venBio is IMMU’s largest stockholder (9.9% of shares outstanding); our interests are aligned with other stockholders to maximize value 2. IMMU’s management and board have overseen decades of value destruction; recent management missteps have further penalized stockholders and im

  4. Slide 4: venBio Select Advisor

    venBio Select Advisor • Public market investment fund focused on innovation within biotechnology sector – Fund launched in 2010 – Team of seasoned investment professionals with medical/scientific backgrounds – IMMU is venBio's first activist situation; activism not regular component of our investmen

  5. Slide 5: IMMU's track record of destroying stockholder value while enriching management

    IMMU’s track record of destroying stockholder value while enriching management 5

  6. Slide 6: Early data of lead drug candidate IMMU-132 supports a significant opportunity

    Early data of lead drug candidate IMMU-132 supports a significant opportunity Early success of lead drug candidate is IMMU-132 • IMMU-132 is being studied for the treatment of Triple Negative Breast Cancer (“TNBC”) • Most aggressive form of breast cancer • significant unmet need • The FDA granted Br

  7. Slide 7: IMMU has a history of drug failures and value destruction

    IMMU has a history of drug failures and value destruction Founded 1982 Nasdaq Comp: +33% Nasdaq Biotech Index: +273% IMMU: -65% *** Market cap $294M* Accumulated deficit $389M** Drugs on market 0 CSO tenure 32 years CEO tenure 15 years UCB licenses Epratuzumab Epratuzumab Clivatuzumab fails again fa

  8. Slide 8: Despite the recent clinical success of IMMU-132, the stock has significantly underperformed

    Despite the recent clinical success of IMMU-132, the stock has significantly underperformed IMMU-132 has enjoyed major clinical … yet IMMU’s stock continues to progress compared to peers … underperform** 1 year 2 year 3 year IMMU ‐10% ‐27% ‐27% IMMU FPRX BPMC ARRY SGEN XNCR IMGN TSRO CLVS MGNXCTMX F

  9. Slide 9: Management's missteps directly contributed to this underperformance

    Management’s missteps directly contributed to this underperformance IMMU stock price surrounding ASCO conference ASCO ejects IMMU for violation of data embargo ASCO selects IMMU- 132 for press Stock declined 62% by the briefing pack end of June vs. pre-ejection share price 6/3/16 6/3/16 6/21/16 Key

  10. Slide 10: Management has failed to execute on striking a pharma partnership

    Management has failed to execute on main corporate goal: striking a pharma partnership to enable approval and advancement of ‘132 to market FY Q4‘16 earnings call: IMMU hires Sol Barer joins as - Work with advisory firm, special advisor to outside Greenhill & Co, Partnering Updates FY Q4’15 strength

  11. Slide 11: IMMU has been unable to retain independent & competent partners

    IMMU has been unable to retain independent & competent partners 2015 2016 2017 Richard L. Sherman DID NOT Mary Paetzold, Donald Stark Chief Medical Officer Dr. Arthur Kirsch STEPPED STAND FOR RE-ELECTION RELPACED from the BoD in Francois Wilhelm DOWN from the board to the board at 2015 response to v

  12. Slide 12: Our experts are skeptical of IMMU's communicated manufacturing strategy and timelines

    Our experts are skeptical of IMMU’s communicated manufacturing strategy and timelines Immunomedics Manufacturing Plan Communicated 1/18/2017 Impossible to validate multi- Suggestion of multiple runs in component pharmaceutical products parallel before a single one is in parallel as this suggests val

  13. Slide 13: Meanwhile, IMMU's management has rewarded themselves generously

    Meanwhile, IMMU's management has rewarded themselves generously 50,000 25 45,000 40,000 20 Total Cumulative Income ($000s) 35,000 30,000 15 Price per Share 25,000 20,000 10 15,000 10,000 5 5,000 0 0 Dec‐99 Dec‐00 Dec‐01 Dec‐02 Dec‐03 Dec‐04 Dec‐05 Dec‐06 Dec‐07 Dec‐08 Dec‐09 Dec‐10 Dec‐11 Dec‐12 Dec

  14. Slide 14: The founder/CSO also benefits from extraordinary self-enrichment arrangements

    The founder/CSO also benefits from extraordinary self-enrichment arrangements David Goldenberg, CSO, Additional Compensation • 0.75% of 3rd party transaction $ • 1.5% of annual net Product revenue* royalties • $150k/yr minimum payment as credit against special incentive programs** Partnership • 20%+

  15. Slide 15: Including ownership in IMMU's IBC subsidiary that enriches him over IMMU stockholders

    … Including ownership in IMMU’s IBC subsidiary that enriches him over IMMU stockholders David Goldenberg decides IMMU … while he owns 18.3% of IBC vs. product ownership rights … 6.8% of IMMU Certain members of our senior management and Board of Directors have relationships and agreements, both with

  16. Slide 16: Management sells shares ahead of a dilutive financing

    Management sells shares ahead of a dilutive financing; dilution that failed to raise the cash needed to fund the required phase 3 study IMMU stock price Jun-Nov 2016 June 6-13 insider selling Goldenberg/Sullivan sell >1M shares October 5, 2016 Financing average price $3.63 ($4.27-$3.02) Terms: $3/sh

  17. Slide 17: IMMU's response to venBio filing: a newly appointed equally unqualified and self-serving BoD

    IMMU’s response to venBio filing: a newly appointed equally unqualified and self-serving BoD 17

  18. Slide 18: IMMU reconstituted its board with a closely linked group

    In response to our proxy filing, IMMU reconstituted its board with a closely linked group that is affiliated with the IMMU board and banker New IMMU Board announced January 12th, 2017 MULTIPLE CURRENT & PRIOR BUSINESS RELATIONSHIPS Brian Jason Markinson Aryeh Robert 12-years on Forrester David the b

  19. Slide 19: The newly appointed IMMU board is highly inter-connected

    The newly appointed IMMU board is highly inter-connected with multiple current and past relationships with Aryeh at the center Husband and Wife Appointed CEO Cynthia Sullivan Financial Hired as Advisor David Goldenberg Relationships Banking Robert Forrester Geoffrey Cox Jason Aryeh Brian A. Markison

  20. Slide 20: QLT: Case study of Aryeh's failed chairmanship

    QLT: Case study of Aryeh’s failed chairmanship Aryeh Appointed Chairman of QLT mid-2012 X • Phase-3 ready • Still awaiting trial start despite 11/20/13 statement that: ‘close to ophthalmology compound finalizing a pivotal trial protocol’ (1) X • Proposed 2 inversions • Company failed to close on eit

  21. Slide 21: As a board member, Jason Aryeh has overseen value destruction and underperformance

    As a board member, Jason Aryeh has overseen value destruction and underperformance PPS under- PPS performed down by ~90% ~50% PPS under- PPS performed down by ~50%* ~ 90% Jason Aryeh joins BoD Source: SEC filings, Bloomberg 21 Ligand, Myrexis relative performance vs. IBB from Aryeh joining BoD to en

  22. Slide 22: Geoffrey Cox has NOT had successful development experience since 1997

    Geoffrey Cox has NOT had successful development experience since 1997 Cox manufacturing experience is irrelevant Beacon Street Advisors, LLC 1984-1997 1997-2001 2001-2010 2010-Present Declining Pharmaceutical development relevance … Cox disappointing leadership PPS DOWN 51% Source: Bloomberg 22

  23. Slide 23: Robert Forrester has failed in the C-suite

    Robert Forrester has failed in the C-suite CEO of Verastem (2012-present) COO of CombinatorX (2005-2009) $140 Forrester $120 appointed CEO $100 Lead drug fails $80 Lead drug $60 fails PPS PPS DOWN $40 DOWN ~90% ~90% Lead drug $20 fails again $0 11/05-12/05 112/06 12/07 12/08 12/09 CombinatoRx Nasdaq

  24. Slide 24: Yet they always get paid: e.g., Jason Aryeh

    Yet they always get paid: e.g., Jason Aryeh … Husband and Wife “Chairman Package” Cynthia Sullivan David Goldenberg Robert Forrester Geoffrey Cox Brian A. Markinson Jason Aryeh IMMU does NOT NEED ANOTHER board with these credentials 24

  25. Slide 25: The new board continues IMMU's past practices of disseminating lies and making baseless threats

    Meanwhile, the new board continues IMMU’s past practices of disseminating lies and making baseless threats IMMUNOMEDICS CLAIMS FACTS • “venBio’s demands for representation • As IMMU’s largest stockholder, our interests are directly and unilateral veto rights are especially aligned with investors, wh

  26. Slide 26: venBio's proposed plan and board expertise

    venBio’s proposed plan and board expertise 26

  27. Slide 27: There is a short window for value creation and the right team is needed

    There is a short window for value creation and the right team is needed – the market has responded favorably to venBio’s proposal Path to Value Creation Market reaction to venBio Filing • Critical path involves securing Accelerated Approval (AA) • IMMU’s capabilities remain unproven in key areas, po

  28. Slide 28: Our nominees are prepared to assume oversight immediately

    Our nominees are prepared to assume oversight immediately and maintain momentum while driving to a clear vision for the future of IMMU Internally Oriented Activities Externally Oriented Activities • Identify key IMMU personnel and • Evaluate strategic options to ensure continuity – develop working a

  29. Slide 29: Our Board Nominees and Advisors provide the necessary expertise

    Our Board Nominees and Advisors provide the necessary expertise to position the company for long-term value creation • Behzad Aghazadeh, PhD – Biotech / Capital Markets Expertise – Portfolio Manager & Managing Partner, venBio Select Advisor    – Formerly Principal Booz Allen (general management c

  30. Slide 30: We have a defined plan with clear objectives

    We have a defined plan with clear objectives … Function Objective Governance • Restore independent & competent governance • Serve fiduciary responsibility to stockholders • Rebuild confidence & credibility with stakeholders Strategy • Evaluate strategic options for IMMU-132 development • Asset and c

  31. Slide 31: … and identified key steps to maximize the potential for IMMU-132

    … and identified key steps to maximize the potential for IMMU-132 Clinical/Organizational – Khalid Islam/Behzad Aghazadeh & Advisory Network Clinical New corporate Organizational Development Decision to partner Audit Finances communication GAP analysis Plan and or go-it-alone plan Detailed Budget Ma

  32. Slide 32: Appendix

    Appendix 32

  33. Slide 33: Appendix: Board Nominee Bio – Behzad Aghazadeh, PhD

    Appendix: Board Nominee Bio – Behzad Aghazadeh, PhD Dr. Behzad Aghazadeh – Dr. Aghazadeh is a Managing Partner and Portfolio Manager of the venBio Select Fund. He brings more than 20 years of experience in the biopharmaceutical industry, including more than 10 years as an institutional investor and

  34. Slide 34: Appendix: Independent Board Nominee Bio – Khalid Islam, PhD

    Appendix: Independent Board Nominee Bio – Khalid Islam, PhD Dr. Khalid Islam – Dr. Islam has over 29 years of experience in the pharmaceutical and biotechnology industry and currently serves as the Managing Director of Life Sciences Management GmbH. He also co-founded Sirius Healthcare Partners, a S

  35. Slide 35: Appendix: Independent Board Nominee Bio – Peter Barton Hutt

    Appendix: Independent Board Nominee Bio – Peter Barton Hutt Peter Barton Hutt – Mr. Hutt is a renowned expert in food and drug law and currently serves as Senior Counsel at Covington & Burling LLP. He began his law practice with the firm in 1960 and has remained at the firm with the exception of ser

  36. Slide 36: Appendix: Independent Board Nominee Bio – Scott Canute

    Appendix: Independent Board Nominee Bio – Scott Canute Scott Canute – Mr. Canute has more than 34 years of experience in the biopharmaceutical industry, having served as President, Global Manufacturing and Corporate Operations at Genzyme Corporation and previously as President of Global Manufacturin

  37. Slide 37: Appendix: Independent Advisor Bio – Richard Heyman, PhD

    Appendix: Independent Advisor Bio – Richard Heyman, PhD Dr. Richard Heyman – Dr. Heyman possesses extensive relevant experience, having served as the co-founder and Chief Executive Officer of Aragon Pharmaceuticals, which focused on androgen receptor signaling inhibitors for the treatment of prostat

  38. Slide 38: Disclosures

    Disclosures Performance Disclosures Unless otherwise indicated, the performance shown is unaudited, net of applicable management, performance and other fees, and expenses, presumes reinvestment of earnings and excludes investor specific sales and other charges. Please refer to the Fund’s Offering Do

Immunomedics — Proxy Contest (January 2017) on 6ix